Phyto chem (India) Limited has announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company's Board of Directors approved these financial statements on February 14, 2026, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The company reported mixed financial performance during the quarter. Key financial highlights include:

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, the company's performance showed:

Regulatory Compliance and Publication

Following the board approval, the company fulfilled its regulatory obligations under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Executive Director Y. Janaki Ramaiah (DIN: 06949910) submitted the newspaper publication compliance to BSE Limited on February 17, 2026.

Board Meeting and Regulatory Compliance

The board meeting was conducted with specific procedural compliance:

The unaudited financial results were reviewed by the Audit Committee before board approval. Managing Director Y. Nayudamma (DIN: 00377721) communicated the results to BSE Limited under the company's disclosure obligations.

Auditor Review and Compliance

Yelamanchi & Associates, Chartered Accountants, conducted a limited review of the financial results. The auditors confirmed that the results were prepared in accordance with Indian Accounting Standards (Ind AS) 34 for interim financial reporting and comply with regulatory requirements.

Company Information

The company operates with its corporate office in Hyderabad and registered office at Bonthapally, Sangareddy District, Telangana. The financial results are available on BSE's website and the company's official website for stakeholder reference.

Phyto chem (India) Limited has formally notified BSE Limited regarding an upcoming board meeting scheduled to review its quarterly financial performance. The pharmaceutical company will present its unaudited financial results for the third quarter of fiscal year 2026, marking a significant milestone in its financial reporting calendar.

Board Meeting Details

The company has scheduled a comprehensive board meeting to address its financial performance for the recent quarter. The meeting will provide stakeholders with insights into the company's operational and financial achievements during the third quarter period.

Financial Results Coverage

The board will consider and approve the unaudited financial results for both the third quarter and nine months ended December 31, 2025. This comprehensive review will provide stakeholders with detailed insights into the company's financial performance across different reporting periods. The results will be prepared in accordance with Regulation 33 of the Securities and Exchange Board of India (LODR) Regulations, 2015.

Trading Window Restrictions

In strict compliance with insider trading regulations, Phyto Chem (India) Limited has implemented comprehensive trading restrictions for its internal stakeholders. The company has closed the trading window for all directors, officers, and designated employees effective January 1, 2026.

Corporate Governance Compliance

The company has demonstrated strong adherence to corporate governance standards by proactively communicating the trading window closure to all relevant personnel. This communication has been circulated to all directors, officers, and designated employees, ensuring complete transparency and compliance with the company's Code of Conduct for Prohibition of Insider Trading. The systematic approach reflects the company's commitment to maintaining the highest standards of corporate governance and regulatory compliance.